Matthew K Robinson
Overview
Explore the profile of Matthew K Robinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dowling J, Nikitin P, Shen F, Shukla H, Finn J, Patel N, et al.
MAbs
. 2023 May;
15(1):2212673.
PMID: 37216961
Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms...
2.
Nikitin P, DiMuzio J, Dowling J, Patel N, Bingaman-Steele J, Heimbach B, et al.
Sci Immunol
. 2022 Jun;
7(75):eabl9943.
PMID: 35771946
Monoclonal antibodies are an efficacious therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape from most of these therapies, outlining the need for...
3.
DiMuzio J, Heimbach B, Howanski R, Dowling J, Patel N, Henriquez N, et al.
Vaccine X
. 2021 May;
8:100098.
PMID: 33937741
Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients...
4.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu A, Minutolo N, Gitto S, et al.
Mol Ther
. 2019 Dec;
28(2):548-560.
PMID: 31870622
The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming...
5.
Burns K, Hensley H, Robinson M, Thevenin D
Mol Pharm
. 2017 Jan;
14(2):415-422.
PMID: 28048942
The targeting of therapeutics specifically to diseased tissue is crucial for the development of successful cancer treatments. The approach here is based on the pH(low) insertion peptide (pHLIP) for the...
6.
DSouza J, Hensley H, Doss M, Beigarten C, Torgov M, Olafsen T, et al.
J Nucl Med
. 2016 Aug;
58(1):175-180.
PMID: 27539844
Methods: The anti-prostate-specific membrane antigen (PSMA) huJ591 antibody (IgG; 150 kDa) and its minibody (Mb; 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) and radiolabeled with...
7.
Lehmann A, Wixted J, Shapovalov M, Roder H, Dunbrack Jr R, Robinson M
MAbs
. 2015 Sep;
7(6):1058-71.
PMID: 26337947
Phage-display technology facilitates rapid selection of antigen-specific single-chain variable fragment (scFv) antibodies from large recombinant libraries. ScFv antibodies, composed of a VH and VL domain, are readily engineered into multimeric...
8.
Ramirez U, Nikonova A, Liu H, Pecherskaya A, Lawrence S, Serebriiskii I, et al.
BMC Cancer
. 2015 May;
15:436.
PMID: 26016476
Background: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making...
9.
DSouza J, Robinson M
Expert Opin Biol Ther
. 2015 May;
15(7):1015-21.
PMID: 25936923
Introduction: Use of mAbs to inhibit signaling through the ErbB receptor tyrosine kinase family has proven to be an effective strategy for treating ErbB-driven cancers. Advances in the field of...
10.
Burns K, Robinson M, Thevenin D
Mol Pharm
. 2015 Mar;
12(4):1250-8.
PMID: 25741818
Localized delivery is vital for the successful development of novel and effective therapeutics for the treatment of cancer. The targeting and delivery described herein is based on the pH (low)...